Business
InMed Files Provisional Patent for Biosynthesis of Cannabinoids
InMed Files Provisional Patent for Biosynthesis of Cannabinoids Canada NewsWire ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Files Provisional Patent for Biosynthesis of Cannabinoids\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Sept. 12, 2017\n\n\n\nCSE: INOTCQB: IMLFF\n\n\n\nVANCOUVER, Sept. 12, 2017 /CNW/ - InMed Pharmaceuticals, Inc. (\"InMed\" or the \"Company\") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announces the filing of a provisional patent application pertaining to the Company's proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.\n\n\n \n \n\n \nThe patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions throughout the world, will provide significant commercial protection for InMed's E. coli-based expression system to manufacture any of the 90+ cannabinoid compounds that may have a medical impact on important human diseases. \n\nThis will be the first in a series of patent applications directed to various aspects of the Company's biosynthesis program. In particular, these applications focus on the superior nature of E. coli-based expression systems over other approaches; gene optimization for maximizing the production of cannabinoids and related compounds; and other proprietary developments and data.  The company will actively convert this and subsequent provisional patents into national-stage filings in all major commercial jurisdictions, in due course. \n\nInMed's cannabinoid biosynthesis program is one of three core assets, which also include the bioinformatics assessment tool to target specific cannabinoids against important diseases, as well as the drug development program, which includes INM-750 for Epidermolysis bullosa and INM-085 for glaucoma.   \n\n\"This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development. The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be over...